Conclusion
In the light of the current results; combined septal and turbinate
injection of BTX-A seems to be a safe and efficient therapeutic choice
for controlling allergic rhinitis symptoms, especially nasal
hypersecretions with a long-lasting effect. Further studies with
extended follow-ups are needed to objectively evaluate the injection
effect, and to determine the efficacy duration and the optimal dose of
BTX-A in allergic rhinitis.